Rani Therapeutics (RANI): Replacing Injections with RaniPill

RANI is a clinical-stage biotech developing an oral delivery platform designed to convert injectable biologics into oral formulations. Injected biologics represent one of the fastest-growing and most lucrative categories in pharmaceuticals, headlined by blockbuster GLP-1 metabolic/obesity drugs, autoimmune therapies and rare disease treatments.

The platform comes in two primary formats:

1.) RaniPill GO: Microtablet formulation delivering up to 3 mg of active drug.

2.) RaniPill HC: High-capacity capsule formulation to deliver larger doses.

How it works: The RaniPill is designed to transit through the stomach and deploy in the small intestine, where the higher pH dissolves the protective outer coating. Once dissolved, intestinal fluids react with internal components to produce carbon dioxide gas. This safely inflates a miniature balloon that deploys a dissolvable microneedle containing the active drug into the intestinal wall, which is a pain-free area with no sharp pain receptors, for direct systemic absorption. The non-dissolving polymer components of RaniPill simply pass through the digestive tract.

Platform Validation: Deals & Institutional Backing: RANI has completed Phase 1 testing in over 100 human subjects across 200+ RaniPill administrations, alongside preclinical testing across 20+ molecules (antibodies, peptides, and large proteins).

The $1B+ Chugai/Roche Agreement: In October 2025, RANI signed a major licensing deal with Roche’s majority-owned subsidiary, Chugai Pharmaceutical. The deal included an upfront payment of $10M, up to $75M in development milestones, $100M in commercial milestones, and royalties for an initial target, with an option to add up to five additional targets (bringing total potential deal value over $1B).

Funding Runway through at least 2027: RANI ended Q2 2026 with $53.4M in cash, providing a cash runway through at least year-end 2027.

Institutional Ownership: Institutional investors (including RA Capital and Samsara BioCapital) hold roughly 50% of outstanding shares.

Key Catalysts & The Metabolic / GLP-1 Pipeline

RT-114 (GLP-1 / GLP-2 Dual Agonist): Developed in partnership with ProGen, initial Phase 1a data in July 2026 showed RT-114 achieved oral bioavailability greater than 150% relative to a matched subcutaneous injection, with no capsule-related adverse events.

RANI has exclusive rights to commercialize and sub-license RT-114 in major markets that include the US, Europe, Canada & Australia. The Company will likely pursue a major partnership agreement(s) after completing the Phase 1b portion of the ongoing clinical trial in 2027. Data from the Phase 1a expansion cohort is expected by year-end 2026 ahead of a planned Phase 1b repeat-dose study in obese patients with data expected in 2027.

PegBio Collaboration: In July 2026, RANI partnered with PegBio to evaluate RaniPill delivery across multiple metabolic and obesity pipeline candidates.

Leadership Advantage: In March 2026, RANI appointed Jesper Høiland (former President of Novo Nordisk U.S.) as Head of Strategy to guide corporate business development and pipeline prioritization.

The Oral Obesity Market Dilemma: Current oral peptide formulations, such as Novo Nordisk’s oral semaglutide (Rybelsus), suffer from very low bioavailability, requiring massive quantities of active drug substance, strict fasting rules, and significant GI side effects. A mechanical delivery system like the RaniPill bypasses enzymatic breakdown in the stomach, creating a compelling value proposition for pharma leaders seeking second-generation oral metabolic therapies.

Technicals: The stock is consolidating near support around its rising 20-day moving average in the upper-$0.80 range, following a crossover through the slower 50-day moving average in early August.

Risks: Clinical trial setbacks, platform safety issues, cash burn/dilution risk, general micro-cap volatility, and need to trade back over $1/share for NASDAQ listing compliance.

Trading under 90 cents with a funding runway through at least year-end 2027 and with multiple shots on goal across large markets, RANI is a compelling high-risk/high-reward biotech stock. The Company’s oral delivery technology has achieved significant validation, including:

1. DATA: Positive clinical data (over 150% bioavailability for RT-114 vs. injection) with no safety issues

2. DEAL: Chugai/Roche deal worth up to $1 billion for six potential programs

3. INVESTORS: Prominent institutional investor ownership and sovereign wealth fund investment

4. PATENTS: Significant IP portfolio that includes over 400 granted patents and pending applications.

Finally, the stock has a history of experiencing exponential gains (illustrated in the 1-year chart below), trading hundreds of millions in volume over several days in October 2025 after the Chugai/Roche deal was announced. While this does not guarantee future trading patterns will be the same, it serves as an excellent precedent that may be repeated when potential licensing agreements or partnerships are announced.

Published on 9/8/26 by Mike Havrilla. Disclosure: I own shares of RANI with a cost basis of 87 cents. Holding for upside clinical and/or deal catalysts.